iFAST Diagnostics

iFAST Diagnostics

A Game-Changing, Low Cost, Rapid Antimicrobial Susceptibility Test - Ensuring The Right Antibiotic On Time, Every Time.

Founded 2022

Southampton, United Kingdom 30 employees Venture round Total: $8.00M Health Care

is a UK-based startup focused on revolutionizing the field of healthcare with its game-changing, rapid antimicrobial susceptibility test. The company's mission is to ensure that every patient with bacterial infections receives the right antibiotic, on time, every time. What sets iFAST apart from conventional tests is its remarkable speed, cost-effectiveness, and reduced need for manual labor. While traditional tests typically take 48-72 hours, iFAST's tests are 10x faster, thus offering a significant improvement in efficiency. With a market worth $4bn, iFAST is poised for success. The company anticipates launching its innovative product by the end of next year. In March 2023, iFAST closed a £2.00M Seed Round investment with backing from notable investors including Future Planet Capital, KHP Ventures, Kadmos Capital Ltd, and QantX. This funding infusion serves as a testament to the potential and viability of iFAST's groundbreaking approach to antimicrobial susceptibility testing.

Funding Stage	Amount	Investors	Lead Investors	Date
Venture round	£5.00M	6	Innovate UK, Cambridge Capital Group +4	27 May 2026
Seed Round	£2.00M	4	Future Planet Capital, KHP Ventures +2	13 Mar 2023
Grant	£1.00M	1	i4i-connect	03 Mar 2023

Funding Stage

Amount

Investors

Lead Investors

Date

Venture round

£5.00M

Innovate UK, Cambridge Capital Group +4

27 May 2026

Seed Round

£2.00M

Future Planet Capital, KHP Ventures +2

13 Mar 2023

Grant

£1.00M

i4i-connect

03 Mar 2023

FAQ About iFAST Diagnostics

A Game-Changing, Low Cost, Rapid Antimicrobial Susceptibility Test - Ensuring The Right Antibiotic On Time, Every Time.

iFAST Diagnostics was founded in 2022.

iFAST Diagnostics is headquartered in Southampton, United Kingdom.

iFAST Diagnostics operates in Health Care. Its work centres on Rapid Antimicrobial Susceptibility Test, Medical Technology, Medtech and Diagnostics.

iFAST Diagnostics has approximately 30 employees.

iFAST Diagnostics has completed 3 funding rounds, raising a total of $8.00M. The latest funding stage is Venture round.

Top alternatives and competitors to iFAST Diagnostics include Pattern Bioscience, First Light Diagnostics, Microplate Dx Limited, Visby Medical, Euroimmun. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

iFAST Diagnostics and Pattern Bioscience are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About iFAST Diagnostics

Funding Rounds & Investors (3)

Latest News

iFAST Diagnostics Alternatives & Competitors

FAQ About iFAST Diagnostics